Sudeep Kundu
- Physiology top 5%
- Immunology top 5%
- Pulmonary and Respiratory Medicine top 5%
- Molecular Biology
- Epidemiology top 10%
- Co-authors
- Brent A. Neuschwander‐TetriYi LuoRose ChristianEdgar D. CharlesDiamant ThaçiSubhashis BanerjeeKim PappTheodore F. Reiss
- Topics
- Psoriasis: Treatment and Pathogenesis (8 papers)Asthma and respiratory diseases (6 papers)Autoimmune Bullous Skin Diseases (4 papers)
- Partner nations
- United StatesGermanyCanada
In The Last Decade
Sudeep Kundu
17 papers receiving 2.0k citations
Hit Papers
Peers
Comparison fields: 5 of 91
- Physiology 761
- Immunology 543
- Pulmonary and Respiratory Medicine 535
- Molecular Biology 459
- Epidemiology 393
Countries citing papers authored by Sudeep Kundu
This map shows the geographic impact of Sudeep Kundu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sudeep Kundu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sudeep Kundu more than expected).
Fields of papers citing papers by Sudeep Kundu
This network shows the impact of papers produced by Sudeep Kundu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sudeep Kundu. The network helps show where Sudeep Kundu may publish in the future.
Co-authorship network of co-authors of Sudeep Kundu
This figure shows the co-authorship network connecting the top 25 collaborators of Sudeep Kundu. A scholar is included among the top collaborators of Sudeep Kundu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sudeep Kundu. Sudeep Kundu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 2 | |
| 3 | Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trialbreakdown → | 219 |
| 4 | Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trialbreakdown → | 173 |
| 5 | 1 | |
| 6 | 19 | |
| 7 | 2 | |
| 8 | Efficacy and Safety of a Potent and Highly Selective Oral Tyrosine Kinase 2 Inhibitor, BMS-986165, in Patients with Moderate-to-Severe Plaque Psoriasis: A Phase II, Randomized, Placebo-Controlled Trial | 1 |
| 9 | 289 | |
| 10 | Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trialbreakdown → | 424 |
| 11 | 210 | |
| 12 | 2 | |
| 13 | 91 | |
| 14 | 68 | |
| 15 | 1 | |
| 16 | 40 | |
| 17 | 424 | |
| 18 | 86 |
About Sudeep Kundu
Sudeep Kundu is a scholar working on Immunology, Physiology and Pathology and Forensic Medicine, having authored 18 papers that have together received 2.1k indexed citations. Recurring topics across this work include Psoriasis: Treatment and Pathogenesis (8 papers), Asthma and respiratory diseases (6 papers) and Autoimmune Bullous Skin Diseases (4 papers). The work is most often cited by research in Immunology and Allergy (214 citations), Physiology (761 citations) and Immunology (543 citations). Sudeep Kundu has collaborated with scholars based in United States, Germany and Canada. Frequent co-authors include Brent A. Neuschwander‐Tetri, Yi Luo, Rose Christian, Edgar D. Charles, Diamant Thaçi, Subhashis Banerjee, Kim Papp, Theodore F. Reiss, Ji Zhang and Melinda Gooderham. Their work appears in journals such as New England Journal of Medicine, The Lancet and CHEST Journal.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.